Immtech International becomes Immtech Pharmaceuticals

New York, March 23 - Immtech International, Inc. said it has changed its name to Immtech Pharmaceuticals, Inc.

The company said the change is intended to reflect its progress toward "developing and commercializing novel pharmaceutical treatments for diseases where there is a clear need for new and improved drug therapies."

"This name change signifies the start of a new era for our company as we move our first oral drug candidate, pafuramidine maleate (DB289), through pivotal clinical trials and toward commercial launch and marketing," said chief executive officer and chairperson Eric Sorkin in a news release.

Immtech is a Vernon Hills, Ill., company working on treatments for infectious diseases including malaria, pneumocystis pneumonia and African sleeping sickness (Trypanosomiasis) and drug development programs for tuberculosis and fungal infections.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.